

Newsletter

A People-Centric Company, IntoinWorld Co., Ltd.
"Connecting People, Advancing Clinical Value."

At IntoinWorld, we strive to be a trusted bridge, safely delivering the value of medical advancements to people. Guided by a human-centered approach, we are committed to growing alongside our clients as true partners.

Established in 2015, IntoinWorld Co., Ltd. is a Contract Research Organization (CRO) specializing in clinical trials across pharmaceuticals, biotechnology, medical devices, investigator-initiated trials (IIT), and observational studies (OS).

With expertise spanning Phase 1 to Phase 3 trials and post-marketing surveillance (PMS), our dedicated team of experienced professionals operates with systematic processes that meet global standards, ensuring accurate and reliable outcomes.

Jung Eun-kyung: "Foreign Drug Price Evaluations to Consider Industry Input, but Pre-Listing System Not Feasible"

The Minister of Health and Welfare stated that the introduction of a foreign drug price comparison reevaluation system will incorporate pharmaceutical industry opinions, taking social acceptability into account. The ministry will closely monitor the U.S. Most-Favored-Nation drug pricing policy and proactively respond. While expanding combination therapies for anticancer drugs is viewed positively, thorough review is necessary. The minister expressed that a pre-listing evaluation system lacks sufficient evidence for implementation. Rapid listing will be considered based on the outcomes of pilot programs.



Trends in the German Bio-Oncology Market

Germany, Europe's largest pharmaceutical market, recorded €55.7 billion in drug sales in 2023, with biopharmaceuticals growing 8.9% to €19.2 billion. The oncology sector, driven by CAR-T therapies and monoclonal antibodies, reached €6.1 billion. AI-driven drug development, gene therapies, and personalized vaccine research are thriving, with the EU investing 2.8 trillion KRW in cancer eradication. Exports of Korean biosimilars surged 123.3% in 2024, reaching \$37.52 million, with market entry expanding through CDMO and local partnerships.



Pharma's 'Secrecy' Hinders Cell and Gene Therapy Development

The development of cell and gene therapies (CGT) is being delayed by a lack of data sharing. Protectionism and proprietary control lead to repeated failures and wasted investments, while the absence of digital infrastructure contributes to flawed clinical trial designs and reduced quality. Experts emphasize the need for collaborative platforms, such as sharing failure case studies and establishing disease registry systems, similar to practices in the aviation industry.

Rapid Growth in the Veterinary Medicine Market: K-PharmaBio Emerges as a New Star

Veterinary medicines are rising as a key export driver, with exports reaching \$167 million by May 2024, a 51% increase. The domestic market is growing, valued at 1.3 trillion KRW, while the global market is projected to reach 103 trillion KRW by 2031. Rising pet ownership is fueling demand for high-quality treatments, and the government aims to nurture a 4 trillion KRW industry by 2035 through R&D support and regulatory easing.



Why CGT Is Being Sidelined: Clear Reasons Emerge Structural Design Key to Regaining Investor Confidence

In 2025, the contraction in cell and gene therapy (CGT) investments has been attributed to high costs, regulatory uncertainties, and challenges with insurance coverage, with venture capital dropping 65% over the past three years. Survival strategies include focusing on commercially viable indications, adopting hybrid models, and securing government support. Companies must build trust through robust technology and market potential, experts suggest.



"Protecting Core Technologies": K-PharmaBio Bolsters Security Measures

Domestic pharmaceutical and biotech companies are intensifying efforts to prevent core technology leaks by strengthening their security systems. They are achieving international information security certifications, such as ISO 27001 and ISO 27701, to enhance their security capabilities. Information security to prevent technology leaks has emerged as a critical factor in maintaining industry competitiveness.

